Toxicological analysis of low-nicotine and nicotine-free cigarettes. 2008

Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
Lombardi Comprehensive Cancer Center, Georgetown University, Georgetown University Medical Center, Washington, DC 20057-1465, USA.

Low-nicotine and nicotine-free cigarettes are commercially available under the brand-name Quest. Some consumers may believe that these are safer cigarettes, and they may smoke more cigarettes or inhale more smoke to compensate for low nicotine yields. Thus, we have studied the toxicological effects of these two cigarettes and compared them with the Kentucky reference cigarette 2R4F. Also, the availability of nicotine-free cigarettes allows for the assessing the role of nicotine in cigarette smoke. In addition to nicotine, some tobacco-specific nitrosamines, aldehydes, and volatile organic compounds were also reduced in the Quest cigarettes compared to the 2R4F. However, aromatic amines were higher in the nicotine-free compared with low nicotine cigarettes. The Ames test revealed that cigarette smoke condensates from the nicotine-free (CSC-F), low nicotine (CSC-L) and 2R4F (CSC-R) cigarettes had a similar mutagenic potency. Exposure to any CSC caused a similar dose-dependent LDH leakage from normal human bronchial epithelial cells. However, CSC-F had more inhibitory effects on the cell growth than CSC-L and CSC-R. Adding nicotine to the CSC-F attenuated this inhibition. Both Quest CSCs decreased gap junction intercellular communication and caused cell cycle arrest. CSC exposure increased cytoplasmic nucleosomes, sub-G1/G0 population and apoptotic comet tails. Proapoptotic protein Bax increased independent of p53 induction after exposure to CSC-F. In conclusion, these studies are not consistent with a perception that low-nicotine or nicotine-free cigarettes may have less toxicity in human cells. Nicotine, as it exists in CSC, attenuates cytotoxicity possibly in part through inhibition of apoptotic pathways.

UI MeSH Term Description Entries
D007770 L-Lactate Dehydrogenase A tetrameric enzyme that, along with the coenzyme NAD+, catalyzes the interconversion of LACTATE and PYRUVATE. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist. Lactate Dehydrogenase,Dehydrogenase, L-Lactate,Dehydrogenase, Lactate,L Lactate Dehydrogenase
D009152 Mutagenicity Tests Tests of chemical substances and physical agents for mutagenic potential. They include microbial, insect, mammalian cell, and whole animal tests. Genetic Toxicity Tests,Genotoxicity Tests,Mutagen Screening,Tests, Genetic Toxicity,Toxicity Tests, Genetic,Genetic Toxicity Test,Genotoxicity Test,Mutagen Screenings,Mutagenicity Test,Screening, Mutagen,Screenings, Mutagen,Test, Genotoxicity,Tests, Genotoxicity,Toxicity Test, Genetic
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D009707 Nucleosomes The repeating structural units of chromatin, each consisting of approximately 200 base pairs of DNA wound around a protein core. This core is composed of the histones H2A, H2B, H3, and H4. Dinucleosomes,Polynucleosomes,Dinucleosome,Nucleosome,Polynucleosome
D012015 Reference Standards A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy. Standard Preparations,Standards, Reference,Preparations, Standard,Standardization,Standards,Preparation, Standard,Reference Standard,Standard Preparation,Standard, Reference
D001980 Bronchi The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI. Primary Bronchi,Primary Bronchus,Secondary Bronchi,Secondary Bronchus,Tertiary Bronchi,Tertiary Bronchus,Bronchi, Primary,Bronchi, Secondary,Bronchi, Tertiary,Bronchus,Bronchus, Primary,Bronchus, Secondary,Bronchus, Tertiary
D002450 Cell Communication Any of several ways in which living cells of an organism communicate with one another, whether by direct contact between cells or by means of chemical signals carried by neurotransmitter substances, hormones, and cyclic AMP. Cell Interaction,Cell-to-Cell Interaction,Cell Communications,Cell Interactions,Cell to Cell Interaction,Cell-to-Cell Interactions,Communication, Cell,Communications, Cell,Interaction, Cell,Interaction, Cell-to-Cell,Interactions, Cell,Interactions, Cell-to-Cell
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell

Related Publications

Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
June 2008, BMJ (Clinical research ed.),
Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
October 2019, American journal of preventive medicine,
Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
December 1993, American heart journal,
Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
April 2016, Tobacco regulatory science,
Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
January 1964, Nauchni trudove na Visshiia meditsinski institut, Sofiia,
Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
July 1953, Journal of the American Medical Association,
Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
November 1983, JAMA,
Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
March 2017, Preventive medicine,
Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
June 1982, British journal of addiction,
Jinguo Chen, and Richard Higby, and Defa Tian, and Duanjun Tan, and Michael D Johnson, and Yingxian Xiao, and Kenneth J Kellar, and Shibao Feng, and Peter G Shields
September 1974, Lancet (London, England),
Copied contents to your clipboard!